Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
评估 Taysha 基因疗法：来自 7 位金融分析师的见解
7 analysts have expressed a variety of opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在过去的一个季度中，有7位分析师对Taysha Gene Therapies（纳斯达克股票代码：TSHA）表达了各种观点，从看涨到看跌，提出了各种各样的观点。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天中情绪的变化，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.71, along with a high estimate of $9.00 and a low estimate of $5.00. This current average reflects an increase of 34.2% from the previous average price target of $5.00.
分析师提供了更深入的见解，确定了12个月的目标股价，平均目标价为6.71美元，最高估计为9.00美元，低估值为5.00美元。目前的平均价格比之前的平均目标价5.00美元增长了34.2％。
Diving into Analyst Ratings: An In...
深入分析师评...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。